TLTFF (Theralase Technologies) Accounts Payable: $0.75 Mil (As of Mar. 2026)


TLTFF Theralase Technologies Inc TLTFF
46 GF Score
Price $0.19
GF Value $0.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Accounts Payable?

Theralase Technologies TLTFF +1.14% 46 Accounts Payable is $0.75 Mil as of Mar. 2026. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Theralase Technologies's Accounts Payable for the quarter that ended in Mar. 2026 was $0.75 Mil.

Theralase Technologies's quarterly Accounts Payable declined from Sep. 2025 ($0.74 Mil) to Dec. 2025 ($0.57 Mil) but then increased from Dec. 2025 ($0.57 Mil) to Mar. 2026 ($0.75 Mil).

Theralase Technologies's annual Accounts Payable declined from Dec. 2023 ($0.51 Mil) to Dec. 2024 ($0.25 Mil) but then increased from Dec. 2024 ($0.25 Mil) to Dec. 2025 ($0.57 Mil).

Theralase Technologies Accounts Payable Related Terms

Theralase Technologies Accounts Payable Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Accounts Payable Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.24 0.51 0.25 0.57

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.78 0.74 0.57 0.75
TLTFF
46GF Score
Theralase Technologies Inc TLTFF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.75 Mil mean?
Theralase Technologies (TLTFF) has a Accounts Payable of $0.75 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Accounts Payable too high?
Theralase Technologies' current Accounts Payable is $0.75 Mil. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Accounts Payable compare to ABT and SYK?
Theralase Technologies' Accounts Payable of $0.75 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Accounts Payable is $0.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.19 — trading 43% above its estimated fair value. The current Accounts Payable is $0.75 Mil. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Accounts Payable is $0.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (TLTFF) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of $0.19 is trading 43% above its estimated GF Value™ of $0.13. GuruFocus considers Theralase Technologies to be Significantly Overvalued.

Key valuation signals for TLTFF:

  • Accounts Payable: $0.75 Mil
  • GF Value™: $0.13 vs. price of $0.19 (43% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TTX:GermanyTLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score

Get the complete analysis for TLTFF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.13
GF Value